News

image

Blocking Cancer in Its Path: New Cellular Defect Discovered

March 16, 2010

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect. According to the study team, ...
image

Pancreatic Cancer Study Reveals Mechanism Initiating Disease, in Mice

March 11, 2010

UCSF scientists have discovered how a mutated gene known as Kras is able to hijack mouse cells damaged by acute pancreatitis, putting them on the path to becoming pancreatic cancer cells. The finding, they say, suggests one way in which the mutated gene -- found ...
image

Breast Cancer Lab Discoveries Quickly Lead to New Clinical Trial

March 3, 2010

A new strategy for treating a common form of breast cancer has emerged from lab studies by UCSF oncologist Mark Moasser, MD. Clinical trials to evaluate the treatment approach already are underway at the UCSF Helen Diller Family Comprehensive Cancer Center. The protocol being evaluated ...
image

UCSF Researchers Identify a Molecular Link between Thymic Tumors and Autoimmunity

February 26, 2010

UCSF researchers have identified a molecular mechanism that explains why patients with tumors of the thymus, or thymoma, often develop autoimmune disorders. The team's findings are published as a case report and letter to the editor in the February 25 issue of the New England ...
image

New Cancer Fighting Strategy Emerges from Antibody Signaling Discovery

February 25, 2010

A new discovery about cancer and the immune system points to previously unrecognized targets for drug development to battle solid tumors. The research also suggests that a drug already in use for more than a decade to treat non-Hodgkin's lymphoma might also be useful in ...
image

UCSF Chancellor Cites Need for Faster Pipeline of Better, Cheaper Drugs for Cancer Patients

February 3, 2010

Before coming to UCSF, Chancellor Susan Desmond-Hellmann, MD, MPH, was a practicing oncologist, and later she was president of product development at Genentech, where she took the lead in developing some of the most successful cancer-fighting drugs in history. Among these drugs are Avastin, Rituxan, ...